论文部分内容阅读
目的探讨碳酸锂对Graves甲亢患者甲状腺131I摄取率的影响及监测碳酸锂使用前后血、尿β2-微球蛋白的水平,了解碳酸锂对肾功能的影响。方法对68例131I摄取率<50%的Graves甲亢患者,在给予碳酸锂(250 mg.次-1,3次.d-1)1周前后,分别测定131I摄取率,以观察碳酸锂对131I摄取率的影响及治疗前后血、尿β2-微球蛋白的水平。结果68例患者服碳酸锂1周后,最高131I摄取率达到73.8%,131I摄取率平均由28.5%±11.7%上升至43.4%±18.3%,平均较原有水平提高14.9%±9.4%(P<0.001);而治疗前后血、尿β2-微球蛋白水平无明显变化。结论碳酸锂能有效提高131I摄取率不够高的Graves甲亢患者的131I摄取率,且肾功能正常时,使用碳酸锂1周对Graves病患者肾功能无不良影响。
Objective To investigate the effect of lithium carbonate on thyroid 131I uptake in patients with Graves’ hyperthyroidism and to monitor the blood and urine β2-microglobulin levels before and after lithium carbonate use, and to understand the effect of lithium carbonate on renal function. Methods Sixty-eight patients with Graves’ hyperthyroidism who had 131I uptake rate <50% were treated with lithium carbonate (250 mg once-1, 3 times daily for 1 week) Uptake rate of blood and urine before and after treatment, β2-microglobulin levels. Results After 68 weeks of lithium carbonate treatment, the highest 131I uptake rate reached 73.8%. The 131I uptake rate increased from 28.5% ± 11.7% to 43.4% ± 18.3% on average, with an average increase of 14.9% ± 9.4% (P <0.001). There was no significant change in blood and urine β2-microglobulin levels before and after treatment. Conclusion Lithium carbonate can effectively improve 131I uptake rate in patients with Graves ’hyperthyroidism, which is not high enough for 131I uptake. When the renal function is normal, using lithium carbonate for one week has no adverse effect on the renal function of patients with Graves’ disease.